Exenatide

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 4592 publications

Effects of insulin and exenatide therapy on glycemic control and β-cell function in patients newly diagnosed with type 2 diabetes and severe hyperglycemia.

Effects of insulin and exenatide therapy on glycemic control and β-cell function in patients newly diagnosed with type 2 diabetes and severe hyperglycemia.

Journal: Journal of the Chinese Medical Association : JCMA

Published: June 15, 2026

Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.

Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.

Journal: Annals of internal medicine

Published: June 15, 2026

Meal Replacement Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease in Adolescents with Severe Obesity.

Meal Replacement Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease in Adolescents with Severe Obesity.

Journal: Childhood obesity (Print)

Published: June 12, 2026

Adjunctive Treatment with GLP-1 and Dual GLP-1/GIP Receptor Agonists for People with Type 1 Diabetes: Consensus Report and Practical Guidelines for Safe Use.

Adjunctive Treatment with GLP-1 and Dual GLP-1/GIP Receptor Agonists for People with Type 1 Diabetes: Consensus Report and Practical Guidelines for Safe Use.

Journal: Diabetes technology & therapeutics

Published: June 05, 2026

IgG Fc-Binding Motif-Conjugated Exendin-4: A Long-Acting Hypoglycemic Agent via Broad-Spectrum Antibody Engagement for Type 2 Diabetes Therapy.

IgG Fc-Binding Motif-Conjugated Exendin-4: A Long-Acting Hypoglycemic Agent via Broad-Spectrum Antibody Engagement for Type 2 Diabetes Therapy.

Journal: Bioconjugate chemistry

Published: May 30, 2026

Cutaneous Variations in Stem-Cell Population in Those on GLP1-Receptor Agonists: A Comparative Controlled Study.

Cutaneous Variations in Stem-Cell Population in Those on GLP1-Receptor Agonists: A Comparative Controlled Study.

Journal: Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]

Published: May 29, 2026

Targeting Inflammation and Fibrosis in Lipedema: The Potential Role of Glucagon-like Peptide-1 Receptor Agonist Therapies.

Targeting Inflammation and Fibrosis in Lipedema: The Potential Role of Glucagon-like Peptide-1 Receptor Agonist Therapies.

Journal: Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]

Published: May 29, 2026

GLPs Significantly Decrease the Risk of Postoperative Surgical Complications: A TriNetX Retrospective Cohort Study.

GLPs Significantly Decrease the Risk of Postoperative Surgical Complications: A TriNetX Retrospective Cohort Study.

Journal: Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]

Published: May 29, 2026

A glucose-responsive dual-nanoparticle-hydrogel-based microneedle patch for co-delivery of insulin and exendin-4.

A glucose-responsive dual-nanoparticle-hydrogel-based microneedle patch for co-delivery of insulin and exendin-4.

Journal: Biomaterials science

Published: May 18, 2026

Potential of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Mitigating Metabolic Side Effects Associated With Clozapine or Olanzapine Therapy: A Literature Review.

Potential of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Mitigating Metabolic Side Effects Associated With Clozapine or Olanzapine Therapy: A Literature Review.

Journal: Cureus

Published: May 17, 2026

Reply: Genetically proxied GLP1R expression does not predict exenatide response in the Exenatide-PD3 trial.

Reply: Genetically proxied GLP1R expression does not predict exenatide response in the Exenatide-PD3 trial.

Journal: Brain : a journal of neurology

Published: May 12, 2026

Glucagon-like Peptide-1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy: Systematic Review and Meta-Analysis.

Glucagon-like Peptide-1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy: Systematic Review and Meta-Analysis.

Journal: Neurology

Published: April 30, 2026

Showing 1-12 of 4,592

Last Updated: 06/30/2026